Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker TAK
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Giles Richard Platford President, IBU | TAK Takeda Pharmaceutical Company Limited | Sale | 55,617 | $20.90 | $1.2M Sale | Form 4 ↗ |
| Nov 2, 2026 | Teresa Marie Bitetti President, OBU | TAK Takeda Pharmaceutical Company Limited | Sale | 46,609 | $20.89 | $973.7K Sale | Form 4 ↗ |
| Sep 14, 2026 | Lauren Rusckowski Duprey Chief Transformation Officer | TAK Takeda Pharmaceutical Company Limited | Sale | 34,535 | $18.54 | $640.3K Sale | Form 4 ↗ |
| Sep 2, 2026 | Andrew Stewart Plump President, R&D, Director | TAK Takeda Pharmaceutical Company Limited | Sale | 116,191 | $18.49 | $2.1M Sale | Form 4 ↗ |
| Aug 19, 2026 | Andrew Stewart Plump President, R&D, Director | TAK Takeda Pharmaceutical Company Limited | Sale | 19,651 | $18.49 | $363.3K Sale | Form 4 ↗ |
| Aug 18, 2026 | Nicola Deidre Petal Greenway Chief Human Resources Officer | TAK Takeda Pharmaceutical Company Limited | Sale | 12,980 | $18.11 | $235.1K Sale | Form 4 ↗ |
| Aug 11, 2026 | Elaine Mary Shannon Pres., Global Supply & Quality | TAK Takeda Pharmaceutical Company Limited | Sale | 20,363 | $17.55 | $357.4K Sale | Form 4 ↗ |
| Aug 10, 2026 | Awny Samaan Botros Farajallah Chief Medical Officer | TAK Takeda Pharmaceutical Company Limited | Sale | 14,006 | $17.10 | $239.5K Sale | Form 4 ↗ |
| Aug 10, 2026 | Ramy Riad Ahmed Ibrahim President, PDT BU | TAK Takeda Pharmaceutical Company Limited | Sale | 7,277 | $17.10 | $124.4K Sale | Form 4 ↗ |
| Aug 10, 2026 | Rhonda Janice Pacheco President, U.S. Business Unit | TAK Takeda Pharmaceutical Company Limited | Sale | 16,901 | $17.10 | $289.0K Sale | Form 4 ↗ |
| Aug 10, 2026 | Lauren Rusckowski Duprey Chief Transformation Officer | TAK Takeda Pharmaceutical Company Limited | Sale | 47,586 | $17.10 | $813.7K Sale | Form 4 ↗ |
| Aug 10, 2026 | Andrew Stewart Plump President, R&D, Director | TAK Takeda Pharmaceutical Company Limited | Sale | 165,393 | $17.10 | $2.8M Sale | Form 4 ↗ |
| Aug 10, 2026 | Agosti Marcello Pignagnoli Head, Strat. & Port. Dev | TAK Takeda Pharmaceutical Company Limited | Sale | 22,957 | $17.10 | $392.6K Sale | Form 4 ↗ |
| Aug 10, 2026 | Teresa Marie Bitetti President, OBU | TAK Takeda Pharmaceutical Company Limited | Sale | 50,012 | $17.10 | $855.2K Sale | Form 4 ↗ |
| Aug 10, 2026 | Elaine Mary Shannon Pres., Global Supply & Quality | TAK Takeda Pharmaceutical Company Limited | Sale | 3,978 | $17.10 | $68.0K Sale | Form 4 ↗ |
| Aug 10, 2026 | Gabriele Ricci Chief Data & Tech. Officer | TAK Takeda Pharmaceutical Company Limited | Sale | 25,088 | $17.10 | $429.0K Sale | Form 4 ↗ |
| Aug 10, 2026 | Nicola Deidre Petal Greenway Chief Human Resources Officer | TAK Takeda Pharmaceutical Company Limited | Sale | 6,774 | $17.10 | $115.8K Sale | Form 4 ↗ |
| Aug 10, 2026 | Julie So-Young Kim President and CEO, Director | TAK Takeda Pharmaceutical Company Limited | Sale | 89,090 | $17.10 | $1.5M Sale | Form 4 ↗ |
| Aug 10, 2026 | Giles Richard Platford President, IBU | TAK Takeda Pharmaceutical Company Limited | Sale | 31,083 | $17.10 | $531.5K Sale | Form 4 ↗ |
| Aug 10, 2026 | Natalie Anne Marie Furney Global General Counsel | TAK Takeda Pharmaceutical Company Limited | Sale | 30,868 | $17.10 | $527.8K Sale | Form 4 ↗ |
| Aug 10, 2026 | Nicola Deidre Petal Greenway Chief Human Resources Officer | TAK Takeda Pharmaceutical Company Limited | Sale | 33,628 | $17.51 | $588.8K Sale | Form 4 ↗ |
| Aug 10, 2026 | Nicola Deidre Petal Greenway Chief Human Resources Officer | TAK Takeda Pharmaceutical Company Limited | Sale | 975 | $17.50 | $17.1K Sale | Form 4 ↗ |
22 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:04 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances